Literature DB >> 30663654

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice.

Gilbert Gastelum1, Eric Y Chang2, David Shackleford3, Nicholas Bernthal3, Jeffery Kraut4, Kevin Francis5, Victoria Smutko1, Patrick Frost6.   

Abstract

Multiple myeloma (MM) tumors engraft in the bone marrow (BM) and their survival and progression are dependent upon complex molecular and cellular interactions that exist within this microenvironment. Yet the BM microenvironment cannot be easily replicated in vitro, which potentially limits the physiologic relevance of many in vitro and ex vivo experimental models. These issues can be overcome by utilizing a xenograft model in which luciferase (LUC)-transfected 8226 MM cells will specifically engraft in the mouse skeleton. When these mice are given the appropriate substrate, D-luciferin, the effects of therapy on tumor growth and survival can be analyzed by measuring changes in the bioluminescent images (BLI) produced by the tumors in vivo. This BLI data combined with positronic-emission tomography/computational tomography (PET/CT) analysis using the metabolic marker 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) is used to monitor changes in tumor metabolism over time. These imaging platforms allow for multiple noninvasive measurements within the tumor/BM microenvironment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30663654      PMCID: PMC9202028          DOI: 10.3791/58056

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.424


  17 in total

1.  Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.

Authors:  Kewal Asosingh; Hendrik De Raeve; Mark de Ridder; Guy A Storme; Angelo Willems; Ivan Van Riet; Benjamin Van Camp; Karin Vanderkerken
Journal:  Haematologica       Date:  2005-06       Impact factor: 9.941

2.  Mechanisms of multiple myeloma bone disease.

Authors:  Deborah L Galson; Rebecca Silbermann; G David Roodman
Journal:  Bonekey Rep       Date:  2012-08-01

3.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 4.  Pathogenesis of myeloma.

Authors:  Kenneth C Anderson; Ruben D Carrasco
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

5.  Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice.

Authors:  Yoshitaka Miyakawa; Yasuyuki Ohnishi; Masashi Tomisawa; Makoto Monnai; Kanoko Kohmura; Yoshito Ueyama; Mamoru Ito; Yasuo Ikeda; Masahiro Kizaki; Masato Nakamura
Journal:  Biochem Biophys Res Commun       Date:  2004-01-09       Impact factor: 3.575

6.  Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

Authors:  P Storti; M Bolzoni; G Donofrio; I Airoldi; D Guasco; D Toscani; E Martella; M Lazzaretti; C Mancini; L Agnelli; K Patrene; S Maïga; V Franceschi; S Colla; J Anderson; A Neri; M Amiot; F Aversa; G David Roodman; N Giuliani
Journal:  Leukemia       Date:  2013-01-24       Impact factor: 11.528

Review 7.  Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Authors:  K Podar; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

8.  Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.

Authors:  Rosemary A Fryer; Timothy J Graham; Emma M Smith; Simon Walker-Samuel; Gareth J Morgan; Simon P Robinson; Faith E Davies
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

9.  A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity.

Authors:  Veena S Mysore; Jerzy Szablowski; Peter B Dervan; Patrick J Frost
Journal:  Mol Cancer Res       Date:  2016-01-22       Impact factor: 5.852

10.  Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis.

Authors:  Patrick Frost; Eileen Berlanger; Veena Mysore; Bao Hoang; Yijiang Shi; Joseph Gera; Alan Lichtenstein
Journal:  J Oncol       Date:  2013-02-28       Impact factor: 4.375

View more
  1 in total

1.  AcidoCEST MRI Evaluates the Bone Microenvironment in Multiple Myeloma.

Authors:  Alecio F Lombardi; Jonathan H Wong; Rachel High; Yajun Ma; Saeed Jerban; Qingbo Tang; Jiang Du; Patrick Frost; Mark D Pagel; Eric Y Chang
Journal:  Mol Imaging Biol       Date:  2021-05-03       Impact factor: 3.484

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.